Nektar Therapeutics | NKTR - Interest Expense On Debt


Nektar Therapeutics reported $7.94M in Interest Expense on Debt for its fiscal quarter ending in March of 2026.





Interest Expense On Debt Change Date
Agios Pharmaceuticals USD 1.11B 76.57M Jun/2026
ALKERMES USD 25.92M 5.03M Jun/2026
Amgen USD 95.64B 94.98B Jun/2026
Baxter International USD 78M 20M Mar/2026
BioCryst Pharmaceuticals USD 21.71M 7.58M Jun/2026
Biogen USD 72.6M 12.6M Jun/2025
Bristol-Myers Squibb USD 407M 4M Jun/2026
Cara Therapeutics -89.64M 128.67M Dec/2025
Cipla INR 170.3M 39M Jun/2026
Dr.Reddys Laboratories INR 1.26B 198M Jun/2026
Eisai JPY 1.96B 409M Jun/2026
Eli Lilly USD 114.7M 134.3M Sep/2025
Exelixis USD 23.4M 3.9M Sep/2023
Gilead Sciences USD 247M 7M Jun/2026
GlaxoSmithKline GBP 121M 46M Jun/2026
Grifols EUR 156.07M 31.46M Sep/2025
Halozyme Therapeutics USD 5.59M 80K Jun/2026
Incyte USD 582K 13K Jun/2026
Ionis Pharmaceuticals USD 18M 1000K Jun/2026
Ironwood Pharmaceuticals USD 8.74M 506K Dec/2024
Karyopharm Therapeutics USD 12.55M 66K Mar/2026
MacroGenics USD 4.89M 1.55M Mar/2026
Merck USD 525M 46M Jun/2026
Nektar Therapeutics USD 7.94M 1.83M Mar/2026
Neurocrine Biosciences USD 1.1M 0 Mar/2024
Novartis USD 462M 119M Jun/2026
Pfizer USD 667M 4M Jun/2026
Roche Holding CHF 304M 7.5M Jun/2025
Sarepta Therapeutics USD 21.51M 205K Jun/2026
Takeda JPY 63.85B 20.2B Jun/2026
Teva Pharmaceutical Industries USD 195M 21M Jun/2026
Xencor USD 7.35M 2.65M Jun/2026